Actinium Pharmaceuticals, Inc (ATNM) is a publicly traded Healthcare sector company. As of May 21, 2026, ATNM trades at $1.20 with a market cap of $36.71M and a P/E ratio of -1.55. ATNM moved +1.30% today. Year to date, ATNM is -19.31%; over the trailing twelve months it is -36.07%. Its 52-week range spans $0.95 to $2.41. Analyst consensus is strong buy with an average price target of $6.00. Rallies surfaces ATNM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Actinium Presents ATNM-400 Mutation-Agnostic NSCLC Data and PSMA-Independent Prostate Efficacy: Actinium will present three abstracts at SNMMI 2026, showcasing ATNM-400’s potent mutation-agnostic activity in KRAS-mutated NSCLC models and efficacy across PSMA-high, PSMA-low and PSMA-negative prostate cancer. Preclinical radiochemistry data reveal optimized chelator-to-antibody ratios, improving 225Ac-antibody tumor targeting, internalization and pharmacokinetics.
| Metric | Value |
|---|---|
| Price | $1.20 |
| Market Cap | $36.71M |
| P/E Ratio | -1.55 |
| EPS | $-0.75 |
| Dividend Yield | 0.00% |
| 52-Week High | $2.41 |
| 52-Week Low | $0.95 |
| Volume | 200 |
| Avg Volume | 0 |
| Revenue (TTM) | $90.00K |
| Net Income | $-23.47M |
| Gross Margin | 0.00% |
3 analysts cover ATNM: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $6.00.